Date: 2025/05/19 - 22:32
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk factors. Tirzepatide's dual effects on GLP-1 and GIP may explain its superior performance.
Date: 2025/05/18 - 16:31
Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular events after just six months of starting the medication, a new study indicates.
Date: 2025/05/17 - 01:32
“Broken heart syndrome” carries a significant risk of death and serious complications. Although the condition appears to be much more common in women, men may be significantly more likely to die from it, according to new research.
Date: 2025/05/13 - 23:32
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers.
Date: 2025/05/12 - 22:00
A 3-month time-restricted eating (TRE) protocol resulted in up to one year of sustained weight loss in people with overweight or obesity. Adhering to an 8-hour window of eating led to greater weight loss than eating throughout the day, whether early or late.
Date: 2025/05/09 - 22:00
Attorneys general in 19 states and Washington, D.C., filed a lawsuit challenging the Trump administration's plans to significantly reduce staffing at the Department of Health and Human Services (HHS), which could disrupt public health services, such as safeguarding food and medication supplies.